Introduction
The RAS association domain family 1A (RASSF1A) gene is located at chromosome 3p21.3 within a specific area of common heterozygous and homozygous deletions (Dammann et al., 2000; Lerman and Minna, 2000) . The RASSF1A gene is one of the most frequently methylation-silenced genes described in human cancer to date (Agathanggelou et al., 2005; Dammann et al., 2005) . Rassf1a À/À mice are prone to both spontaneous tumorigenesis and carcinogen-induced tumorigenesis (Tommasi et al., 2005; van der Weyden et al., 2005) , supporting the notion that RASSF1A is a bona fide tumor suppressor. However, it is not fully understood how RASSF1A is involved in tumor suppression. The biochemical function of the RASSF1A protein is largely unknown. The homology of RASSF1A with the mammalian Ras effector novel Ras effector (NORE)1 suggests that the RASSF1A gene product may function in signal transduction pathways involving Ras-like proteins. However, recent data indicate that RASSF1A itself binds to RAS only weakly and that binding to RAS may require heterodimerization of RASSF1A and NORE1 (Ortiz-Vega et al., 2002) . In addition, there is evidence for an association of both NORE1 and RASSF1A with the pro-apoptotic kinase MST1 and that this interaction is involved in apoptosis induced by activated Ras .
Recently, several groups, including ours, have reported that RASSF1A is a microtubule-and centrosome-associated protein, which regulates mitotic progression (Liu et al., 2003 (Liu et al., , 2005c Dallol et al., 2004; Rong et al., 2004; Song et al., 2004; Vos et al., 2004) . We have shown that overexpressed RASSF1A co-localized with microtubules in interphase cells and with spindles and centrosomes during mitosis (Liu et al., 2003) . Forced expression of RASSF1A induced mitotic arrest with aberrant mitotic cells (Liu et al., 2003) . Similar results been have been obtained by several other groups Rong et al., 2004; Song et al., 2004; Vos et al., 2004) . Song et al. (2004) have reported that RASSF1A regulated mitosis by inhibiting the anaphasepromoting complex (APC) through binding to CDC20 and induces G 2 -M arrest at pro-metaphase. The function of RASSF1A was independent of the protein early mitotic inhibitor 1, and therefore Song et al. (2004) proposed that RASSF1A acted in early prometaphase to prevent the degradation of mitotic cyclins and to delay mitotic progression. However, our laboratory has been unable to confirm an interaction between RASS-F1A and CDC20 . RASSF1A may function as a tumor suppressor through promoting apoptosis and/or by controlling mitotic cell division (Agathanggelou et al., 2005; Dammann et al., 2005) . However, its exact mechanism of action remains to be determined.
Aurora-A belongs to a family of highly conserved serine/threonine kinases, which includes Aurora-A, -B and -C in mammals. Aurora kinases combined with cyclin-dependent kinase 1 (or p34 cdc2 ), Polo-like kinases and NIMA-related kinases are four families of known mitotic kinases that regulate mitotic progression. All three members of the Aurora kinase family share a conserved C-terminal catalytic domain and have been found to have multiple mitotic functions (Andrews et al., 2003; Carmena and Earnshaw, 2003) . Among them, Aurora-A is the most intensively studied one. Originally Aurora-A was identified in a screen for Drosophila melanogaster mutants that have abnormal spindle-pole phenotypes (Glover et al., 1995) . Aurora-A is located on centrosomes from late S/early G 2 to the time when the cells exit mitosis (Carmena and Earnshaw, 2003) . Aurora-A is important in centrosome maturation and separation as well as in spindle assembly (Andrews et al., 2003; Carmena and Earnshaw, 2003; Marumoto et al., 2005) . Moreover, activity of Aurora-A is required for timely mitotic entry (Marumoto et al., 2002 Hirota et al., 2003; Hachet et al., 2007; Portier et al., 2007) . Both upregulation and downregulation of Aurora-A results in cytokinesis failure Anand et al., 2003; Marumoto et al., 2003; Zhang et al., 2004) , indicating that the timing of Aurora-A activity is important for proper cytokinesis.
Expression and localization of Aurora-A is cell-cycle regulated. Its protein level peaks in the middle of mitosis and is diminished in late mitosis/early G 1 by the Cdh1-activated APC/C (APC/cyclosome) (Honda et al., 2000; Castro et al., 2002; Taguchi et al., 2002) . The activity of Aurora-A is also controlled by phosphorylation. Phosphorylation of Thr288 of human Aurora-A is essential for its kinase activity (Walter et al., 2000; Littlepage et al., 2002) . Several activators of Aurora-A have been identified, which include TPX2, Ajuba, HEF1, Bora and PAK1 (Kufer et al., 2002; Hirota et al., 2003; Crane et al., 2004; Satinover et al., 2004; Pugacheva and Golemis, 2005; Zhao et al., 2005; Hutterer et al., 2006) . Activation of Aurora-A by TPX2 is required for bipolar-spindle assembly (Trieselmann et al., 2003; Tsai et al., 2003) , whereas activation of Aurora-A by Ajuba is essential for mitotic entry . It is tempting to propose that Aurora-A activators may at least partially control the temporal and spatial distribution of Aurora-A activity along the cell division cycle.
Aurora-A is frequently overexpressed in various human tumors (Bischoff et al., 1998; Zhou et al., 1998) . Overexpression of Aurora-A was sufficient to transform NIH3T3 and Rat1 cells (Bischoff et al., 1998; Zhou et al., 1998) . However, the same regimen did not transform primary murine embryonic fibroblasts (MEFs), suggesting that upregulation of Aurora-A itself is insufficient for oncogenesis (Anand et al., 2003) . It is still unclear whether overexpression of Aurora-A induces mammary tumors in transgenic mouse models Wang et al., 2006) . Being a multifunctional protein, it is not known which function of Aurora-A contributes to its oncogenic activity. Current thought is that overexpression induces centrosome defects, mitotic abnormalities and aneuploidy, which leads to cancer (Meraldi et al., 2004; Giet et al., 2005; Weaver and Cleveland, 2006) . Being a putative oncogene, Aurora-A has attracted a great deal of attention as a potential antitumor target (Keen and Taylor, 2004; Mortlock et al., 2005; Naruganahalli et al., 2006 ).
Here we demonstrate that endogenous RASSF1A interacts with and activates Aurora-A.
Results

RASSF1A regulates centrosome separation
RASSF1A is a microtubule-and centrosome-associated protein in interphase cells and is found at the spindle poles and midzone region in mitotic cells (Liu et al., 2003 (Liu et al., , 2005a Dallol et al., 2004; Rong et al., 2004; Vos et al., 2004; van der Weyden et al., 2005) . Endogenous RASSF1A is primarily a centrosomal protein in interphase cells (Guo et al., 2007) and it colocalizes with mitotic spindles in mitosis ( Figure 1a ). Using EGFP-tagged deletion fragments of RASSF1A, we determined that the centrosome and spindle pole localization of RASSF1A requires a minimal domain fragment from amino acid D120 to G193 (Figure 1b ). This domain is distinct from the RAS association domain present in RASSF1A (R194-S288) and only partially overlaps with the minimum microtubulebinding domain (D120-S288) (Liu et al., 2003) .
Previously, we found that overexpression of RASS-F1A resulted in over 50% of mitoses with monopolar spindles (Liu et al., 2003) . Generally, monopolar spindles may result from defects in centrosome duplication or from failure of centrosome separation. When these cells were stained with an anti-g-tubulin antibody, we observed that there were two closely spaced g-tubulin spots in 96% of the monopolar spindle containing cells, which indicates that the centrosomes have duplicated but were not separated far enough to organize a bipolar spindle (Figure 2 ).
Microtubules are important in centrosome separation (Waters et al., 1993; Gaglio et al., 1996; Uzbekov et al., 2002) . Therefore, we speculated that inhibition of microtubule dynamics by RASSF1A may at least in part account for its effect on centrosome separation. Indeed, the monopolar spindles were hyperstabilized and resistant to nocodazole-induced depolymerization (Figure 2 ).
RASSF1A interacts with Aurora-A
We asked if there are other mechanisms by which RASSF1A may regulate centrosome separation. It is known that Eg5 and Aurora-A are required for centrosome separation (Blangy et al., 1995; Glover et al., 1995; Gaglio et al., 1996) . We reasoned that proteins, which can affect Eg5 or/and Aurora-A function, may affect centrosome separation. To test if RASSF1A interacts with Aurora-A and/or Eg5, we transfected GST-RASSF1A or GST-only into COS-7 cells. Aurora-A but not Eg5 was detected in the pulldown product from GST-RASSF1A-expressing cells (Figure 3a) , indicating an interaction between RASS-F1A and Aurora-A. To rule out the possibility that this interaction might be an artifact of RASSF1A overexpression, we performed a co-immunoprecipitation assay using anti-RASSF1A antibodies. Anti-RASSF1A antibodies, but not the control IgG, co-immunoprecipitated endogenous Aurora-A (Figure 3c ). To determine whether RASSF1A interacts with Aurora-A directly or indirectly, we carried out an in vitro binding assay. Maltose-binding protein (MBP)-tagged recombinant RASSF1A but not MBP alone can bind to His-tagged Aurora-A directly (Figure 3b) . Surprisingly, MBPtagged recombinant RASSF1C can only bind to Histagged Aurora-A weakly ( Figure 3b ). As RASSF1A and RASSF1C only differ in their N termini, we reasoned that either the RASSF1A N terminus is required to bind to Aurora-A or that the RASSF1C N terminus prevents RASSF1C from binding to Aurora-A. The C-terminal catalytic domain of Aurora-A was both sufficient and required for Aurora-A to bind to RASSF1A ( Figure 4a ). As this catalytic domain is well conserved among Aurora-A family members, we propose that Figure 1 Centrosome association of RAS association domain family 1A (RASSF1A). (a) Endogenous RASSF1A localizes to centrosomes and their associated mitotic spindles in GM004427F human fibroblasts. GM004427F cells were co-stained with anti-RASSF1A antibody, anti-g-tubulin antibody and 4,6-diamidino-2-phenylindole (DAPI). Although RASSF1 predominantly colocalizes with centrosome in interphase cells, it resides in both centrosome and mitotic spindle in mitosis. (b) Centrosome association domain mapping of RASSF1. COS-7 cells were transfected with the indicated EGFP-tagged RASSF1 deletion constructs and the subcellular localization of theses mutants was visualized using florescence microscopy.
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RASSF1A may also interact with Aurora-B and Aurora-C. Indeed, we found that both Aurora-B and Aurora-C could bind to RASSF1A when they were overexpressed in COS-7 cells (Figures 4b and c) .
To further explore the interaction between RASSF1A and Aurora-A, we co-stained GM004427F human fibroblasts with an anti-RASSF1A antibody and an anti-Aurora-A antibody. In interphase cells, RASSF1A locates predominantly at centrosomes, but Aurora-A largely resides in the cytoplasm. When cells progress into prophase, Aurora-A starts to accumulate on centrosomes where RASSF1A stays ( Figure 5 ). In metaphases, both RASSF1A and Aurora-A were found on centrosomes (spindle poles) as well as the associated spindles. In anaphase and telpophase, both RASSF1A and Aurora-A colocalized on the centrosome and midzone region ( Figure 5 ). The same mitotic stagespecific co-localization pattern was observed when EGFP-tagged RASSF1A and endogenous Aurora-A were co-localized (data not shown).
RASSF1A regulates Aurora-A activation As overexpression of RASSF1A and inactivation of Aurora-A leads to the same phenotype, known as monopolar spindle mitoses, we hypothesized that RASSF1A negatively regulates Aurora-A function. There are at least four possible ways by which RASSF1A could inhibit Aurora-A. First, RASSF1A may repress Aurora-A expression or promote Aurora-A degradation. To test this possibility we quantitated Aurora-A expression in both Rassf1A þ / þ MEFs and Rassf1A À/À MEFs using western blot. We did not find any significant difference in terms of Aurora-A expression at the total protein level although we did notice a slight reduction of the slower migrating (presumable phosphorylated) protein band in Rassf1A À/À MEFs after nocodazole treatment (Supplementary Figure 1) . Second, RASSF1A may regulate localization of Aurora-A. Aurora-A was not mislocalized when RASSF1A was absent in Rassf1a À/À MEFs (Supplementary Figure 1) . Third, RASSF1A may inhibit Aurora-A kinase activity directly. In an in vitro kinase assay, we did not detect any inhibitory effect of RASSF1A on Aurora-A (Supplementary Figure 2) , though recombinant RASS-F1A is a substrate of Aurora-A in vitro (Supplementary Figure 2) consistent with a recent report (Rong et al., 2007) . Fourth, RASSF1A may inhibit Aurora-A activation that subsequently leads to negative regulation of Aurora-A. To test this, we knocked down RASSF1A by siRNA in HeLa cells. Consistent with what we found in RASSF1A-deficient MEFs, downregulation of RASS-F1A in HeLa cells did not change the total protein level of Aurora-A (Figure 6 , compare lanes 8, 9 or 10 with lanes 13 or 14). Given that phosphorylation of Aurora-A on Thr288 leads to activation of Aurora-A, we Centrosomes are duplicated but not separated. Middle and bottom rows, COS-7 cells transfected with EGFP-RASSF1A (middle) or the EGFP-RASSF1A 120-288 deletion mutant (bottom) were incubated with 20 mM nocodazole for 1 h. Cells were double stained with anti-a-tubulin antibody (red) and 4,6-diamidino-2-phenylindole (DAPI) (blue). RASSF1A interacts with and activates Aurora-A L Liu et al examined the phosphorylation status of Thr288 by an antibody specific for phosphorylated Thr288 of human Aurora-A. Surprisingly, downregulation of RASSF1A resulted in a marked decrease of Aurora-A phosphorylation on Thr288 (Figure 6 , compare lanes 8, 9 or 10 with lanes 13 or 14) when the cells are synchronized to mitosis by nocodazole. As Aurora-A expression is diminished in interphase cells and Aurora-A is solely phosphorylated and activated in mitosis, we did not expect to detect any significant Aurora-A phosphorylation change in the randomly growing cells (Figure 6 , compare lanes 1, 2, or 3 with lanes 6 or 7). To rule out the possibility that cell-cycle distribution may be involved in this decreased phosphorylation of Aurora-A, we probed the same membrane with an antibody against a mitotic marker, histone H3 phosphorylated on Ser10. We did not detect any significant difference of Ser10 phosphorylation of histone H3 between RASS-F1A siRNA-treated cells and control LacZ siRNAtreated cells (Figure 6 , compare lanes 8, 9 or 10 with Figure 5 Endogenous RAS association domain family 1A (RASSF1A) colocalizes with Aurora-A in mitosis. GM004427F, SV-40 immortalized human fibroblasts, were fixed and co-stained with an anti-Aurora-A antibody and an anti-RASSF1A antibody. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). Cells at each mitotic stage are as indicated.
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RASSF1A interacts with and activates Aurora-A L Liu et al lanes 13 or 14), indicating that cell-cycle distribution did not contribute to the reduced phosphorylation of Aurora-A in RASSF1A siRNA-treated cells.
To further investigate the role of RASSF1A in Aurora-A activation, we overexpressed either RASSF1A or RASSF1C in HeLa cells. Overexpression of RASSF1A promoted Aurora-A activation, as indicated by an increase of phosphorylation of Aurora-A on Thr288 in nocodazole-treated cells (Figure 7) . However, such an increase was not proportionally dependent on RASSF1A expression level. For instance, transfection of 1 mg RASSF1A plasmid had a greater effect on Aurora-A phosphorylation than transfection of 2 or 4 mg RASSF1A. One possible explanation would be that at high expression levels, RASSF1A may act differently compared to low RASS-F1A levels. For example, overexpression of RASSF1A stabilizes microtubules only when RASSF1A is expressed at low to moderate levels but not when it is expressed at high levels (L Liu and GP Pfeifer, unpublished observation). Further investigation is warranted to reveal whether RASSF1A's effect on microtubules has any relationship with RASSF1A's effect on Aurora-A activation. Strikingly, overexpression of RASSF1C did not have an effect on Aurora-A activation (Figure 7 ), indicating that RASSF1A and RASSF1C may play opposite roles in Aurora-A activation. Indeed, overexpression of RASSF1C inhibited Aurora-A phosphorylation compared to control (Figure 7) . Therefore, a balance between RASSF1A and RASSF1C might be important for Aurora-A regulation. In cancer cells, such a balance is disrupted by loss of RASSF1A expression.
Although downregulation of RASSF1A in HeLa cells did not change the protein level of Aurora-A (Figure 6 ), downregulation of Aurora-A by siRNA did decrease RASSF1A protein levels, especially in synchronized mitotic HeLa cells (Figure 6 ), suggesting that Aurora-A might regulate RASSF1A expression or stability.
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However, the mechanism of this regulation remains unknown.
Discussion
The centrosome was first described by Boveri (1888) . Over the past 100 years centrosomes have been known as microtubule-organizing centers that nucleate microtubule arrays in animal cells. Not until recently, we started to appreciate that centrosomes function beyond being structural scaffolds for microtubules. Instead, centrosomes are the sites that anchor and integrate various regulatory activities, which are required for cellcycle control (Doxsey, 2001a, b; Rieder et al., 2001; Doxsey et al., 2005) . For instance, the centrosome is required for both G 1 -S cell-cycle progression (Hinchcliffe et al., 2001 ) and cytokinesis (Piel et al., 2001) , whereas centrosomal localization of Aurora-A is essential for mitotic entry (Hachet et al., 2007; Portier et al., 2007) . Although it has been well established that overexpressed RASSF1A colocalizes with microtubules in interphase (Liu et al., 2003 (Liu et al., , 2005a Dallol et al., 2004; Rong et al., 2004; Vos et al., 2004; van der Weyden et al., 2005) , the endogenous RASSF1A protein is primarily a centrosome-associated protein in interphase cells. One simple explanation for such a discrepancy is that overexpression of RASSF1A saturates its binding sites on the centrosome; therefore excessive cytoplasmic RASSF1A is forced to bind to cytoplasmic microtubules. Consistent with such a notion, we found that when RASSF1A expression was low in an inducible system, it colocalized with centrosomes but not microtubules in interphase cells (data not shown). It has been reported that Aurora-A can phosphorylate RASSF1A (Rong et al., 2007 ) (see also Supplementary Figure 2) . This phosphorylation might modulate RASSF1A's ability to bind to microtubules, as a phosphorylationmimicking mutant of RASSF1A could not interact with microtubules, whereas a phosphorylation-defective mutant could (Rong et al., 2007) . However, endogenous RASSF1A localizes predominantly at centrosomes but not microtubules in interphase cells (Guo et al., 2007 ; Figure 1 ). As Aurora-A is inactivate in G 1 (Honda et al., 2000; Castro et al., 2002; Taguchi et al., 2002) and expression of RASSF1A is constant throughout the cell cycle (L Liu and GP Pfeifer, unpublished observation), it is very likely that something other than phosphorylation by Aurora-A prevents RASSF1A from binding to microtubules in G 1 . This could be another kinase that phosphorylates RASSF1A in interphase and prevents it from binding to microtubules but cannot phosphorylate an excess of overexpressed RASSF1A. By controlling the dynamics of microtubules, RASSF1A might regulate centrosome separation, at least upon overexpression (Figure 2) .
The centrosomal localization of RASSF1A might implicate RASSF1A in cell-cycle regulation. As Rassf1a-deficient mice are viable and fertile (Tommasi et al., 2005; van der Weyden et al., 2005) , it is unlikely that RASSF1A has an essential role in cell-cycle control. Instead RASSF1A may fine-tune cell-cycle progression or its role is redundant with that of other proteins, for example, its closest homologue NORE1A. Cytokinesis failure occurs more frequently in Rassf1a À/À MEFs than in wild-type MEFs (Guo et al., 2007) . The mechanistic basis for cytokinesis failure in Rassf1a À/À MEFs is not clear although it is at least in part a consequence of lack of activation of the mitotic exit kinase LATS1 (Guo et al., 2007) . As Aurora-B, which is required for cytokinesis (Giet and Glover, 2001; Guse et al., 2005) , interacts with RASSF1A (Figure 4b) , it is possible that loss of RASSF1A impedes Aurora-B function. Our failure to detect an endogenous interaction between RASSF1A and Aurora-B (data not shown) might suggest that the abundance of such an interaction is low or that this interaction is transient in nature. Further investigation is required to dissect the functional significance of the Aurora-B-RASSF1A interaction, which might shed light on how RASSF1A is involved in cytokinesis.
It came as a surprise that RASSF1A is an activator of Aurora-A. RASSF1A has been proven to be a tumor suppressor (Tommasi et al., 2005; van der Weyden et al., 2005) , whereas Aurora-A fits the criteria to be classified as an oncoprotein (Bischoff et al., 1998; Zhou et al., 1998; Ewart-Toland et al., 2003 . This calls into question whether activation of Aurora-A by RASSF1A contributes to RASSF1A's tumor suppressive function. However, it has been reported that both downregulation and upregulation of Aurora-A leads to cytokinesis defects Anand et al., 2003; Marumoto et al., 2003; Zhang et al., 2004) , suggesting that not only the level of expression but also the proper timing of Aurora-A activation and inactivation is important for cytokinesis. Activation and localization of Aurora-A is tightly regulated. The temporal and spatial distribution of Aurora-A activity is at least partially controlled by Aurora-A activators. For instance, activation of Aurora-A by TPX2 is required for bipolar-spindle assembly (Trieselmann et al., 2003; Tsai et al., 2003) , whereas activation of Aurora-A by Ajuba is essential for mitotic entry . Activation of Aurora-A by HEF-1 in a nonmitotic pathway is mandatory for the disassembly of the primary cilium (Pugacheva et al., 2007) . RASSF1A is a residential centrosomal protein, whereas Aurora-A is recruited to centrosomes during G 2 /M phase. It is not clear when and how RASSF1A activates Aurora-A. Recombinant RASSF1A did not activate recombinant Aurora-A in vitro (Supplementary Figure 2) , suggesting that RASS-F1A itself is not sufficient to activate Aurora-A. It is possible that RASSF1A functions as a scaffold to bring together Aurora-A and its activator(s). On the other hand, we cannot exclude the possibility that posttranslational modifications of RASSF1A, which could not be achieved in Escherichia coli, are required for RASSF1A to activate Aurora-A.
Loss of RASSF1A leads to a downregulation of Aurora-A activity. To achieve suitable Aurora-A activity for cell growth, cells may compensate the Aurora-A activation deficit in cells not expressing RASSF1A by gene amplification. This gene amplification may finally override the loss of RASSF1A effect and result in Aurora-A overexpression and subsequent tumorigenesis. Therefore, it will be of interest to determine whether Aurora-A amplification and overexpression correlates with RASSF1A methylation silencing in primary human tumors. Aurora-A expression levels and gene amplification in the tumors developing in Rassf1a À/À mice will also need to be determined.
Materials and methods
Cell culture and transfection COS-7, HeLa and 293T cells were obtained from the ATCC and the GM004427F cell line, an SV-40 immortalized human skin fibroblast line was purchased from the Coriell Institute for Medical Research (Camden, NJ, USA). All cell lines were cultured in high glucose Dulbecco's modified Eagle's medium with 10% fetal bovine serum. COS-7 and 293T cells were transfected using FuGENE6 (Roche, Indianapolis, IN, USA) following the manufacturer's instructions. We used previously reported methods (Abbondanzo et al., 1993) to isolate and culture primary MEF derived from 13.5 day embryos from Rassf1a À/À and Rassf1a þ / þ mice (Tommasi et al., 2005) .
Plasmid constructs
To generate EGFP-, GST-, Flag-and MBP-tagged RASSF1A/ RASSF1C constructs, the cDNA encoding human RASSF1A/ RASSF1C was subcloned into EGFP-C2 (Clontech, Palo Alto, CA, USA), pEGB (kindly provided by Dr J Avruch, Massachusetts General Hospital), Flag-pcDNA3.0 and pMAL-c2 Â (New England Biolabs (NEB), Ipswich, MA, USA) vectors. The truncated mutant RASSF1A sequences were generated by a single-step PCR using EGFP-RASSF1A as template and cloned into EGFP-C2 (Clontech) and pMALc2 Â (NEB) vectors. Aurora-A constructs were kindly provided by Erich Nigg (Max Planck Institute for Biochemistry, Martinsried, Germany). The cDNAs of Aurora-B and Aurora-C were purchased from Open Biosystems (Huntsville, AL, USA). Each of them was cloned into HA-pcDNA3.0 to generate HA-Aurora-A, HA-Aurora-B and HA-Aurora-C. The truncated mutant Aurora-A sequences were generated by a single-step PCR and cloned into the c-Myc-pcDNA3.0 vector.
Protein purification
The pMAL protein fusion and purification system (NEB) was used to purify MBP-tagged RASSF1A, RASSF1C and their truncated mutants according to the manufacturer's instructions. ER2508 (NEB), a protease-deficient strain of E. coli, was used to express the fusion proteins. The cells were lysed by sonication in column buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM EDTA and 1 mM dithiothreitol (DTT)) containing protease inhibitor cocktail (Roche) and the lysate was cleared by centrifugation at 9000 g at 4 1C for 30 min. After incubating the supernatant with amylose resin (NEB) for 2 h at 4 1C, the mixture was loaded onto a chromatography column (Bio-Rad, Hercules, CA, USA) and washed with 12 column volumes of column buffer. Fusion protein was eluted with column buffer containing 10 mM maltose. His-Aurora-A was purified using Ni-NTA agarose (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The construct of GST-Lats2-79-118 was a kind gift from Dr H Nojima (Osaka University, Japan) (Toji et al., 2004) . GST-Lats2-79-118 protein was purified using glutathione sepharose 4B (Amersham, Piscataway, NJ, USA) according to the manufacturer's instructions.
Antibodies
To generate polyclonal antibodies against RASSF1A, the polypeptides MBP-RASSF1A 1-119 and MBP-RASSF1A 120-340 were used to immunize rabbits. The antibodies were immunopurified by passing through Affi-Gel 10 (Bio-Rad) conjugated with MBP-RASSF1A. Three antibodies were generated, named M3-04, M5-05 and M5-06, respectively. M3-04 is against MBP-RASSF1A 1-119 that is specific for RASSF1A (Guo et al., 2007) , whereas M5-05 and M5-06 are against MBP-RASSF1A 120-340, which is shared by both the RASSF1A and RASSF1C isoforms. Monoclonal antibody against RASSF1A (clone 3F3) was from Abcam (Cambridge, MA, USA) (used in western blotting).
Polyclonal antibodies against Aurora-A (BL469, BL656) were purchased from Bethyl Laboratories (Montgomery, TX, USA). BL469 recognizes human Aurora-A, whereas BL656 reacts with mouse Aurora-A. Mouse monoclonal anti-Aurora-A antibody (clone 35C1) was obtained from Abcam and phospho-specific polyclonal antibody against Aurora-A (Thr288) was from Cell Signaling Technology (Danvers, MA, USA). Rabbit polyclonal antibodies against Flag and c-Myc tags and mouse monoclonal antibodies against btubulin (clone TUB 2.1), g-tubulin (clone GTU-88) and b-actin (clone AC-15) were from Sigma. Anti-phospho-histone H3 (Ser10) was from Upstate (Lake Placid, NY, USA). Anti-MBP antibody was from New England Biolabs. Anti-HA polyclonal antibody was from Bethyl Laboratories.
Immunofluorescence microscopy Cells were cultured in six-well plates containing coverslips coated with poly-L-lysine (Sigma). After 24-48 h, the cells were fixed in À20 1C methanol for 5 min. After incubation with 1% bovine serum albumin in phosphate-buffered saline (PBS) for 30 min, the cells were incubated with the indicated primary antibodies and appropriate secondary antibodies (Invitrogen, Carlsbad, CA, USA) sequentially. DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI; Sigma). Images were obtained with an Olympus IX81 automated inverted microscope equipped with a Spot RT Slider high-resolution cooled CCD color camera (Olympus; Melville, NY, USA). Color images were processed using Photoshop 9.0 (Adobe Systems; San Jose, CA, USA) or ImagePro Plus (Media Cybernetics; Silver Spring, MD, USA).
Western blot and immunoprecipitation
Cells were lysed in lysis buffer (10 mM Tris-HCl, pH 8.0, 1% NP40, 150 mM NaCl and 1 mM EDTA), containing phosphatase inhibitors (20 mM b-glycerolphosphate, 50 mM sodium fluoride and 1 mM Na 3 VO 4 ) and protease inhibitor cocktail (Roche).
For immunoprecipitation with anti-Flag antibody, the EZview Red Anti-Flag (M2) affinity gel (Sigma) was used according to the manufacturer's instruction. For immunoprecipitation with anti-RASSF1A antibodies (M3-04, M5-05), HeLa cells were synchronized by thymidine (2 mM, 17h) followed by nocodazole (200 nM, 20 h). Total cell lysates were incubated with these antibodies for 4 h followed by incubation with Protein A/G plus agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 4 1C.
For western blots, proteins were fractionated by electrophoresis on a 10% or 6-18% gradient SDS-polyacrylamide (PAGE) gel and transferred to an immunoblot polyvinylidene fluoride (PVDF) membrane (Bio-Rad). The blots were probed with the indicated primary antibodies followed by appropriate secondary antibodies conjugated with horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA, USA). The signals were detected using ECL Plus (Amersham).
In vivo GST pull-down assay At 60-72 h after transfection with GST-RASSF1A or pEBG (GST) vector alone, 293T cells were harvested and lysed in ice-cold cytoskeleton lysis buffer (0.5% Nonidet P-40, 10 mM piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), pH 7.0, 50 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1mM ethylene glycol tetraacetic acid, 1 mM DTT, 1 mM Na 3 VO 4 ) with protease inhibitor cocktail (Roche, Indianapolis, IN, USA). The lysates were incubated with glutathione sepharose 4B gel (Amersham) for 45 min at room temperature and the gel was sedimented at 500 g for 5 min. After five times of washing with PBS, the glutathione sepharose pellet was collected and the bound proteins were eluted with 1 Â SDS loading buffer with heating at 95 1C for 5 min. The eluted proteins were fractionated by electrophoresis on a 10% SDS-PAGE gel and transferred to an immunoblot PVDF membrane (Bio-Rad). The blots were probed with the indicated antibodies.
In vitro protein binding assay Purified MBP-RASSF1A, MBP-RASSF1C or their truncated mutants were incubated with His-Aurora-A in binding buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, pH 8.0, 0.025% NP-40, 1 mM DTT, 10% glycerol) at 4 1C for 1 h. The mixture was adsorbed onto amylose resins (NEB). The resins were washed five times with binding buffer. The bound proteins were analysed by western blot using antibodies against MBP and Aurora-A.
In vitro kinase assay Recombinant His-Aurora-A (0.5 mg) was incubated with either MBP-RASSF1A (4 mg) or MBP2 (4 mg) in kinase buffer (25 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 5 mM MnCl 2 , 1 mM NaF, 5 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 , 1 mM DTT) supplemented with 20 mM ATP, 10 mCi [g-32 P]ATP and 2 mg GST-Lats2-79-118 as substrate at 30 1C. COS-7 cells cotransfected with Flag-Aurora-A and HA-RASSF1A were lysed in lysis buffer (10 mM Tris-HCl, pH 8.0, 1% NP40, 150 mM NaCl, 1 mM EDTA) containing phosphatase inhibitors (20 mM b-glycerolphosphate, 50 mM sodium fluoride and 1 mM Na 3 VO 4 ) and protease inhibitor cocktail (Roche). The lysates were incubated with EZview Red Anti-Flag (M2) affinity gel (Sigma). After washing with kinase buffer, the pellets were incubated with 2 mg GST-Lats2-79-118 in kinase buffer supplemented with 20 mM ATP and 10 mCi [g-32 P]ATP at 30 1C for 30 min. Reactions were stopped by the addition of 2 Â SDS-PAGE sample buffer. Proteins were analysed by 15% SDS-PAGE followed by autoradiography. At last, the gel was stained with Coomassie blue (Bio-Rad).
siRNA For siRNA the following sequences were used: RASSF1A, RA196, 5 0 -GACCUCUGUGGCGACUUCAtt-3 0 (nucleotides 196-214 relative to the start codon) (Shivakumar et al., 2002) , RA1404, 5 0 -GGUUUUGGAUCUUGAAUGUtt-3 0 (nucleotides 1404-1422 relative to the start codon) and RA1430, 5 0 -GGAUAUCCUUAUCAGAGCUtt-3 0 (nucleotides 1430-1448 relative to the start codon). Aurora-A, AUA725, 5 0 -AUGCCCUGUCUUACUGUCA-3 0 (Kufer et al., 2002 ) and AUA155, 5 0 -AUUCUUCCCAGCGCGUUCC-3 0 . An siRNA sequence targeting the LacZ gene (LacZ, 5 0 -CGUACGCGGAAUACUUCGAtt-3) was used as a control. RA196 specifically targets RASSF1A, whereas RA1404 and RA1430 target both RASSF1A and RASSF1C. All oligonucleotides were purchased from Ambion and delivered into HeLa cells using Oligofectamine (Invitrogen). HeLa cells were harvested 72 h after transfection.
Abbreviations
APC, anaphase-promoting complex; DAPI, 4,6-diamidino-2-phenylindole; MBP, maltose-binding protein; MEF, mouse embryonic fibroblast; MTOC, microtubule-organizing center; NORE, novel Ras effector; RASSF1A, RAS association domain family 1A.
